
Mechanistic insights into ApoE4 dose effects on serum metabolites in Alzheimer's Disease

a Data Science approach

George Miliarakis

MSc Thesis
Wageningen University & Research
Wageningen, March 2024

Supervisor


C.F.W. Peeters

Mathematical & Statistical Methods (Biometris)
Wageningen University & Research

Supervisor

Yannick Vermeiren

Nutrition, Brain and Cognitive Ageing
Wageningen University & Research



FOREWORD

This is where you type your foreword. In the Foreword the student states clearly his/her contribution that originates from the master thesis project, and, if applicable, what contribution(s) possibly followed from the student's internship on the same topic. It is also stated in the foreword what data sources were used, and whether the data have a degree of confidentiality. In addition, possible acknowledgements may be made to people who have contributed to (certain parts of) the thesis.

ABSTRACT

This is where you type your abstract. The abstract must be communicable to a broad audience and contain, next to a summary text, an outreach item such as an infographic or a link to a video/website/web application. Such as, for example, the nice figure below.

ABBREVIATIONS

- ABCA1:** ATP-binding cassette transporter A1. 4
ANOVA: Analysis of Variance. 9
ApoE: Apo-lipoprotein E. 4
ATP: Adenosine tri-phosphate. 5
AUC: Area Under the ROC curve. 11
- BBB:** blood-brain barrier. 4
- CSF:** cerebrospinal fluid. 3
- FA:** Factor Analysis. 10
FAD: familial Alzheimer's Disease. 1
- GGM:** Gaussian graphical model. 11
GSK-3 β : Glycogen synthase kinase-3 β . 6
- HDL:** high density lipoprotein. 4
- IDL:** intermediate density lipoprotein. 4
- LASSO:** Least Absolute Shrinkage and Selection Operator. 10
LOAD: late-onset Alzheimer's Disease. 1
- ML:** Maximum Likelihood. 10
MNL: Multinomial Logistic Regression. 10
- NF κ B:** nuclear factor kappa B. 4
- RSS:** Residual Sum of Squares. 10
- SAD:** sporadic Alzheimer's Disease. 1
SMOTE: Synthetic Minority Over-Sampling Technique. 10
- TLR4:** toll-like receptor 4. 4
- VCS:** Version Control System. 9
VLDL: very low density lipoprotein. 4

CONTENTS

Foreword	i
Abstract	ii
Abbreviations	iii
1. Introduction	1
1.1. Alzheimer's Disease	1
1.1.1. Amyloid cascade hypothesis	1
1.2. Human apolipoprotein-E gene	1
1.2.1. ApoE4 and Alzheimer's Disease	1
1.2.2. ApoE and ancestry in Alzheimer's Disease	2
1.2.3. ApoE and sex synergy in Alzheimer's Disease	2
1.2.4. Evolution of ApoE over time	2
1.2.5. Tissue expression	3
1.3. Apo-lipoprotein E	4
1.3.1. Structure and function	4
1.3.2. ApoE isoforms	4
1.3.3. Lipidation nuances of ApoE isoforms	4
1.3.4. Interplay between ApoE lipidation and Alzheimer's Disease	5
1.4. ApoE4-mediated metabolic changes in Alzheimer's Disease	6
1.4.1. Measured in <i>post-mortem</i> brain tissue	6
1.4.2. Measured in blood	6
1.5. Research Questions	7
2. Data	8
3. Methodology	9
3.1. Data management	9
3.2. Data exploration and Visualisation	9
3.3. Data Wrangling and Feature Engineering	9
3.4. Statistical Analysis	9
3.4.1. ApoE4 dose effects on plasma metabolite levels in AD	9
3.4.2. Global testing	9
3.4.3. Machine Learning	10
3.4.4. Network analysis	11
3.5. R Packages	12
4. Results	13
4.1. Data Exploration and Visualisation	13
4.1.1. AD group	13
4.1.2. SCD and AD	13
4.2. RQi - Differential expression of plasma metabolites per ApoE4 dose among AD and SCD	13
4.2.1. Global Test	13
4.2.2. Hierarchical Global ANCOVA on Generalised Linear Models	13
4.2.3. ANOVA on Nested Linear Models	13
4.3. RQii - Classification of metabolites on ApoE4 presence	14
4.3.1. Benchmark model: clinical factors only	14
4.3.2. Fitting the full metabolomic panel, correcting for clinical factors	14
4.3.3. Fitting the metabolomic ML-estimated 6-factor Latent Projection	14
4.4. RQiii - Covariance Network analysis of metabolites	14
5. Discussion	15

1. INTRODUCTION

1.1. Alzheimer's Disease. Alzheimer's Disease (AD) is a complex, progressive neurodegenerative disorder and the most common form of dementia [1]. It was considered the 6th leading cause of death in the US in 2019, with an overall increase of 145% in mortality from 2000 to 2019 [2]. The impact AD has on patients, their caregivers, and healthcare systems is detrimental. Despite decades of research, factors to prevent, slow or cure AD remain to be discovered.

Age is the main risk factor for AD, while several genetic and lifestyle risk factors, as well as biochemical pathways contribute to its development [1]. AD occurs in various histopathological phenotypes and presents a broad spectrum of clinical signs and symptoms [3, 4]. The AD continuum starts with subjective cognitive decline (SCD), followed by mild cognitive impairment (MCI) [5], and continues with progressive loss of global cognition, of which particularly memory, processing speed and executive functioning, spanning a total period of 10-15 years [6].

Sporadic or late-onset AD (SAD, LOAD; 95% of cases) is the most frequent phenotype, typically appearing after 65 years of age [7]. A rarer phenotype is early-onset familial AD (FAD), usually starting at ages 30–65 and passed in an autosomal dominant fashion [8]. Even though FAD mutations explain only a small percentage of AD cases, they have a great impact on AD research given their appealing genotype-phenotype links.

1.1.1. Amyloid cascade hypothesis. The amyloid plaque hypothesis has dominated the scientific discussion on the pathogenesis of AD. In historical terms, its impact was profound, as it helped distinguish and identify AD as a single disease that may be studied for treatment [9]. It suggests that chronic neuroinflammation promotes protein misfolding and accumulation in the brain, forming plaques (consisting of oligomerized amyloid $A\beta_{42}$) and tangles (consisting of hyperphosphorylated tau protein) [4]. Nevertheless, it does not necessarily cover all AD cases; clinical trials of $A\beta$ anti-bodies as treatment prove the amyloid cascade hypothesis as insufficient [10, 11]. Evidence suggests that oxidative stress, metabolic abnormalities, atherosclerosis, cardiovascular effects, imbalances of intra-neuronal calcium and other metal ions contribute to the development of AD [10]. Kepp *et al.* propose a more complex and holistic view of AD pathology, by integrating (epi-)genetic, environmental, vascular, neuro-inflammatory and metabolic factors in predictive models [10].

1.2. Human apolipoprotein-E gene. LOAD is consistently shown associated with the gene that encodes apolipoprotein-E (ApoE) [12]. The structure and function of ApoE, as well as how the first defines the latter is described in section 1.3.

1.2.1. ApoE4 and Alzheimer's Disease. Humans present three variants of the ApoE gene: ϵ_2 , ϵ_3 and ϵ_4 [13, 14], resulting in six genotypes [Fig. 1]. In caucasian populations, the most abundant allele is ApoE3 (rs7412 C/rs429358 T), with a frequency of 78%, and is considered neutral regarding the risk of AD [15]. ApoE4 (rs7412 C/rs429358 C) has a frequency of 14% and represents the strongest genetic risk factor for LOAD, with gene dose effects [16]. Conversely, ApoE2 (rs7412 T/rs429358 T) is found in 8% of Caucasian populations, and carriers of this allele exhibit a reduced risk of LOAD [15]. The various ApoE alleles are strongly linked to the primary pathological features of LOAD, namely amyloid- $A\beta$ and phosphorylated tau [17]. While the association between ApoE alleles and LOAD risk or protection is observed across diverse ancestral backgrounds, the strength of this association varies [18, 19], see section 1.2.2.

1.2.2. ApoE and ancestry in Alzheimer's Disease. The majority of studies exploring the relationship between ApoE alleles and the genetics of LOAD have primarily focused on Northern European populations [14]. However, smaller studies involving diverse ancestral backgrounds show variations in ApoE4 allele [14]. While ApoE4 is present in 14% of Caucasian Americans, its prevalence increases to 40% among African Americans, 37% in Oceania, and 26% in Australia. Southern Asia and Europe exhibit ApoE4 allelic frequencies of less than 10%, compared to Northern Europe where it rises to 25% [18, 20–22].




FIGURE 1. Sankey chart showing the allele distribution among the 6 ApoE genotypes.

The epidemiological impact of ApoE alleles also differs among populations. In Korea, Japan, and Japanese-American communities, ApoE4 confers a higher risk of LOAD compared to Caucasians [19]. Conversely, for Native Americans, Hispanic Americans, African Americans, and those of African descent, ApoE4 is associated with a lower risk of LOAD than in Caucasian-American populations [19, 23–26]. A recent study in a Chinese population found that ApoE3 is more protective than ApoE2 [27]. Some of these population-specific effects are attributed to the ApoE haplotype [23, 25]. A recent discovery of a novel locus (19q13.31) could contribute to attenuating ApoE4-mediated AD risk in African Americans [28].

1.2.3. ApoE and sex synergy in Alzheimer's Disease. Notably, sex (60% females) and ApoE4 allelic composition (50% has at least one ϵ_4 allele) are the strongest genetic risk factors for SAD [29]. In this regard, it is shown that the ApoE4 genotype has a larger impact on females, as they present greater impairment of mitochondrial energy production, compared to males [29, 30].

1.2.4. Evolution of ApoE over time. Interestingly, humans are the only species exhibiting polymorphism in the ApoE gene [30]. All other animal species have one ApoE variant, which resembles the human ApoE3 allele [31]. ApoE4 is the oldest human allele, followed by ApoE3 and ApoE2 in age [30]. ApoE4 may be adaptive, reducing mortality in highly infectious environments, with food scarcity and shorter lifespans [32]. However, as human environments became less septic, with food abundance and longer life expectancy, ApoE4 started to burden the arteries and brain, increasing the risk of diseases related to ageing [30]. The emergence of ApoE3 from ApoE4 putatively reflects the shift in human diet from a plant-based one to a meat-rich one, where genes adaptive to high meat consumption were and still are vital to regulate increased cholesterol levels [33].

1.2.5. Tissue expression. The principal producers of ApoE are hepatocytes in the liver [34]. In the CNS, ApoE is primarily expressed in glia, astrocytes, cells of which modulate metabolic homeostasis and neuronal communication, followed by microglia, the brain immune cells [35]. Each genotype is linked to different expression levels [13]. ApoE2 carriers seem to have higher cerebrospinal fluid (CSF) levels of ApoE, compared to ApoE4 carriers [36, 37].




FIGURE 2. Linear representation of the ApoE protein. Three structural domains are highlighted: N-terminal, hinge and C-terminal domains. The different aminoacids at positions 112 and 158 are shown per common alleles and aminoacids at positions 136, 236 and 251 coded by rarer alleles. [38]

1.3. Apo-lipoprotein E.

1.3.1. Structure and function. ApoE is a brain-specific lipid-binding glycoprotein of 299 amino-acids (34 kDa) that comprises several types of lipoproteins, i.e., chylomicra, IDL and VLDL [13]. Its main function in the brain is the transport of lipids (mainly cholesterol) through membrane receptors [14]. Moreover, its isoforms have an effect on diverse cellular functions, e.g. synaptic integrity, glucose metabolism, A β clearance, blood-brain barrier (BBB) integrity and mitochondrial regulation [13]. How these relate to AD pathology will be elaborated in section 1.3.4.

1.3.2. ApoE isoforms. The nuances in the amino acid composition of ApoE, specifically the presence of cysteine or arginine at positions 112 and 158, significantly impact its binding with lipids and receptors [30]. The most prevalent isoform, ApoE3, features cysteine at position 112 and arginine at position 158 [30], as shown in Fig. 2. ApoE2 has two cysteines, while ApoE4 has two arginines at these positions [30]. The C-terminal domain of ApoE (positions 273–299) is crucial for its lipidation specificity and efficiency [39].

1.3.3. Lipidation nuances of ApoE isoforms. For ApoE to exert its effects, it needs to be lipidated [13]. ApoE undergoes lipidation via ATP-binding cassette transporter A1 (ABCA1), a lipid efflux protein [40, 41]. The lipidation degree varies among ApoE isoforms, with ApoE4 exhibiting the least efficient lipidation [39, 42]. This discrepancy in lipidation has been linked to alterations in lipoprotein size and type, in that ApoE4 “prefers” large triglyceride-rich VLDL, while ApoE2 and ApoE3 have a higher affinity for phospholipid-rich HDL particles [43]. The lower affinity of ApoE4 for HDL particles leads to increased levels of unlipidated ApoE, resulting in its aggregation [44]. Moreover, ApoE4 fibrils are more neurotoxic than those of ApoE2 and ApoE3 [45].

Poor lipidation leads to poor ApoE recycling [30]. The latter favors the entrapment of ABCA1 in endosomes, away from the cell membrane, thereby pooling cholesterol in the cell membrane rather than attaching it to HDL particles [46]. This increased cholesterol content in the cell membrane amplifies toll-like receptor 4 (TLR4) signaling in macrophages, activating NF κ B and inducing an inflammatory gene response [30]. ApoE4 accumulation also sequesters insulin receptor (IR) in endosomes, impacting cellular energy preferences [47]. This leads to a decrease in glucose utilization for ATP production and an increase in fatty acid oxidation [48].

1.3.4. Interplay between ApoE lipidation and Alzheimer’s Disease. As mentioned earlier, ApoE isoforms have differential pleiotropic effects on various cellular functions. ApoE4 induces pro-inflammatory response,




FIGURE 3. Schematic overview of A β -independent effects of ApoE in AD pathology. The isoform-dependent effects of ApoE are indicated. Abbreviations: apoE, apolipoprotein E; NFT, neurofibrillary tangle; BBB, blood brain barrier; IL, interleukin; TNF- α , Tumor necrosis factor- α ; ROS, reactive oxygen species. [13]

leading to the dysfunction of BBB, which in turn impairs cognitive functions [49–51]. Moreover, ApoE modulates the primary neuropathological hallmarks of AD: neuroinflammation, A β plaques and tau tangles [13]. Evidence from human and transgenic mice studies reveals increased brain A β and amyloid plaque loads in ApoE4 carriers, compared to ApoE3; with the lowest levels in ApoE2 carriers [52–54]. Higher plaque loads are associated with ApoE4 due to its higher affinity for A β and poor clearance capacity [51]. Additionally, high levels of ApoE4 in neurons remarkably increase tau protein phosphorylation, while high concentrations of ApoE3 don't seem to have an effect [55–58]. Notably, ApoE directly inhibits phosphorylation of tau by GSK-3 β [59]. An overview of the A β -independent effects of ApoE is shown in Fig. 3.

1.4. ApoE4-mediated metabolic changes in Alzheimer's Disease. Metabolism entails the repertoire of chemical reactions that keep living organisms alive. Metabolites –especially lipid [60–62]–, perceived as functional intermediates of AD development, are rigorously studied for bio-markers or targets for treatment [63].

1.4.1. *Measured in post-mortem brain tissue.* A metabolomic profiling of brain tissue, obtained *post-mortem* from AD patients and healthy controls showed pronounced impairments in sterol and sphingolipid levels in ApoE4 carriers with AD [64]. However, another *post-mortem* metabolomic analysis didn't reveal nuances significantly correlated with ApoE4 [65], although they showed trends in increased cholesterol esters, unsaturated lipids, and sphingomyelin species.

1.4.2. *Measured in blood.* Transcriptomic and lipidomic analyses in humanized ApoE mice associated ApoE4 with decreased free fatty acid levels, many increased tricarboxylic acid (TCA) cycle metabolites, as well as changes in plasma levels of phosphatidylcholines and unsaturated fatty acids [66, 67]. A recent study on 58 individuals found six downregulated plasma metabolites (including lysophospholipids and cardiolipin) in ApoE4 carriers [68]. Further, the plasma metabolome of the latter reveals a preference for aerobic glycolysis [69]. Significant correlations of ApoE genotype and sex with metabolites were observed, i.e. several phosphatidylcholines were found in a large study of more than 1500 individuals [29]

Perturbed serum metabolites associated with AD are aminoacids, amines [70, 71], cholesteryl esters [62], sphingolipids [60, 63, 71–73], fatty acids [61, 70], glycerophospholipids [72, 74–76], phosphatidylcholines [77] and lipid peroxidation compounds [61]. These molecules are usually identified via high-throughput metabolomic pipelines (coupled with Mass Spectrometry (MS) detectors) that trace all compounds in a sample and result in high-dimensional data [78]. The latter often require advanced statistical methods e.g. projection to latent structures [76, 79] or graphical models [80] in order to extract putatively meaningful information. With such techniques, de Leeuw et al. discovered distinct serum metabolic signatures among AD patients-controls and those carrying at least one ApoE ϵ_4 allele [70], as they appear in Fig. 2. The different metabolic profiles, however, among ApoE4 non-carriers remain obscure. The present data science approach shows ApoE4-mediated differentially expressed metabolites, potentially unveiling distinct pathways of metabolic deregulation in AD.




FIGURE 4. Mutual (left-hand panel) and distinct(right-hand panel) metabolic network topologies between ApoE ϵ 4 carriers and non-carriers in AD, as published by de Leeuw et al.. Red edges represent links that are present exclusively in ApoeE ϵ 4 carriers with AD. Green edges represent connections found in the SCD group. Solid edges represent positive partial correlations, while dashed edges represent negative partial correlations. Abbreviations: SCD, subjective cognitive decline

1.5. Research Questions. ApoE ϵ 4 carriers –particularly females– experience metabolic disturbances and are at increased risk of SAD. The mechanistic links, however, between ApoE4 dose, metabolism and AD development are not entirely known [61]. Tracking ApoE4 dose effects on serum metabolites can reveal metabolic perturbations preceding or co-existing with AD. Hence, in an effort to elucidate ApoE4-mediated changes in serum metabolites in AD and SCD, one could state the following research questions (RQ):

Are there mechanistic links between ApoE4 dose and serum metabolome in AD?

- (1) Are there ApoE4 dose effects on serum metabolite levels in AD?
- (2) How discriminatory are serum metabolites of ApoE4 status and/or AD?
- (3) How do the covariance network topologies of metabolites differ between ApoE4 carriers and non-carriers?

2. DATA

The data were collected from 127 AD patients and 120 SCD ($n = 247$) individuals in the context of the Amsterdam Dementia Cohort [70, 81]. In this study two data sets were used: a targeted metabolomics panel and clinical background data, i.e. age at diagnosis, sex, smoking status, alcohol consumption, hypertension (and medication), hyperlipidemia (and medication), anticoagulant medication, anti-depressants, mean arterial pressure (MAP) and body mass index (BMI). The metabolomics set contains $p = 230$ metabolites (amines, organic acids, lipids and oxidative stress compounds). The methodology for the metabolomic analysis and ApoE genotyping can be found at de Leeuw et al.'s Blood-based metabolic signatures in Alzheimer's Disease [70]: SMT1 . The data was cleaned as described in the same article. The resulting data set is high-dimensional, in the sense that it contains more variables than observations ($p > n$). Another particularity of the data is the covariance and collinearity of the variables. Therefore, appropriate measures need to be taken to prevent model over-fitting –the algorithm being unable to distinguish signal from noise and fitting the latter– and to correct for spurious correlations.

3. METHODOLOGY

3.1. Data management. The FAIR principles for data management and stewardship in science were published by Wilkinson *et al.* in 2016 [82]. FAIR stands for Findable, Accessible, Interactive, and Reusable data; the intention is to create and use data that are well-documented and reproducible. These principles were considered at every step of the study and implemented when applicable. All analysis was performed in R (version 4.3.2), and the current report was written in L^AT_EX (Tex Live version 2023). All files are committed to a private Github repository –with git as Version Control System (VCS).

3.2. Data exploration and Visualisation. An interactive correlation heatmap was created to visualise the Pearson correlation coefficients using the package *heatmaply*.

3.3. Data Wrangling and Feature Engineering. The data were processed using base R and *dplyr* [83].

3.4. Statistical Analysis.

3.4.1. ApoE4 dose effects on plasma metabolite levels in AD. A straight-forward way to test whether metabolites are distinctly expressed depending on ApoE4 dose, controlling for clinical variables, is ANOVA (Analysis of Variance) on p nested linear models. The dependent variable in each model is a metabolite; the nested model, eq. (1), has only clinical variables, while the full model, eq. (2), features the clinical variables, plus the number of ApoE4 alleles (0, 1 or 2) as explanatory variables. Let m_j represent the j -th metabolite, x_k the k -th clinical variable, and D the ApoE4 dose; the nested models then are:

$$(1) \quad m_j = \beta_0 + \sum_{k=1}^m \beta_k x_k + \varepsilon$$

$$(2) \quad m_j = \beta_0 + \sum_{k=1}^m \beta_k x_k + \beta_{m+1} D_{\varepsilon 4} + \varepsilon$$

Then, for every $j = 1, \dots, p$ the hypothesis test is $H_0: \beta_{m+1} = 0$ vs $H_a: \beta_{m+1} \neq 0$. Under H_0 the test statistic, F follows an $F_{1, n-(m+2)}$ distribution. This implies p hypothesis tests, which qualifies as multiple testing. A method to treat the latter is controlling False Discovery Rate [84], that is controlling the expected ratio of incorrectly rejected hypotheses, globally e.g. at an α of .05. The caveat of this approach is that minor changes in metabolite levels may not be identified. The next section introduces the concept of a *global test* to deal with this issue.

3.4.2. Global testing. A more elegant alternative to multiple testing is global test [85]. The concept was first introduced by Simon *et al.*, and proposed an approach based on permutations to cater to the high dimensionality of gene expression data.

The R package *GlobalTest* [86–88] developed by Goeman *et al.* originally fits a logistic regression model, using genes to predict the response $Y \in [1, \dots, k]$ (or k), representing clinical or biological group membership. This method is also appropriate for other types of -omics data, such as metabolomics in this study [88]. The hypothesis test is that metabolite levels are independent of the ApoE4 dose X , i.e. $H_0: P(Y|X) = P(Y)$, where $X \in \mathbb{R}^{n \times p}$. The tests uses the -usually- low-dimensional ($n \times n$) the intra-sample covariance matrix instead of the larger ($p \times p$) metabolite covariance matrix. Hence, this method is rather efficient. The test statistic under H_0 follows, asymptotically, a normal distribution. In other words, this method tests whether the metabolite levels are discriminating over the dose of ApoE4. The *gt()* function of the package was used to screen for differences in metabolite levels based on the ApoE4 dose. The *covariates()* function was used to visualise the ApoE4 dose effects on metabolite levels.

Inspired by global testing, a global ANCOVA method was introduced by Mansmann *et al.* and extended by Hummel *et al.*, featuring (generalised) linear model comparison based on the extra sum of squares (SS) principle [91]. This method tests whether the gene expression or metabolite levels are independent of the response variable, i.e. $H_0: P(X|Y = 1) = P(X|Y = k)$. The high dimensionality is treated

by aggregating the residual sums of squares (RSS) of individual models to the RSS of a global model [91]. The test statistic uses the aggregated RSS and under H_0 follows, asymptotically, a χ^2 -distribution. The R package `GlobalAncova` also features a hierarchical generalised linear model comparison function, `gGlobalAncova.hierarchical()` that enables the modeling of (metabolic) pathways. This function was used to test for nuances depending on the 4-class variable ApoE4AD.

3.4.3. Machine Learning. The degree to which a user can understand and interpret the prediction or decisions made by a statistical model is defined as *interpretability* [92]. It is of interest in this study to find the optimal balance between the performance of a model with its interpretability. The *bias-variance trade-off* was formally introduced by Geman *et al.* and refers to the trade-off between the accuracy (opposite of bias) and precision (opposite of variance) of a prediction. It also refers to the trade-off between model flexibility (or complexity) and interpretability [93]. One needs to consider this trade-off during model and evaluation method selection, as some impose more bias or variance than others.

The R package `caret` streamlines the training and comparison of classification and regression models, offering broad parametrization options [94]. The functions `trainControl()`, `train()` and `confusionMatrix()` were used to fit and evaluate the models. A sampling method used to deal with the unbalanced classes was SMOTE (Synthetic Minority Over-Sampling Technique), as implemented by the package `DMwR2` [95].

Considering interpretability, Multinomial Logistic Regression (MNL) is inherently interpretable. Let $y = k$, with $k \in N, [1, 4]$ representing the k -th class of ApoE4AD and β_{kj} its set of coefficients, β_{lj} the coefficients of the rest of classes for j -th metabolite, then a MNL model calculated the probability

$$\Pr(y = k|X = x) = \frac{e^{\sum_{j=1}^p \beta_{kj}x_j}}{\sum_{l=1}^4 \sum_{j=1}^p e^{\beta_{lj}x_j}}$$

When $p > n$, the coefficient estimation method has low bias and high variance, in that small changes in the training data can result in very different coefficient estimates [96]. Regularization trades off a small increase in bias for a great decrease in variance, by shrinking the unimportant coefficients towards zero. LASSO (Least Absolute Shrinkage and Selection Operator) [97], also called L1-regularization shrinks the MNL coefficients to 0, thus weeding out spurious correlations and reducing the number of predictors [97]. It does so by introducing the term

$$\lambda \sum_{j=1}^p |\beta_j|$$

where $\lambda \geq 0$ is a tuning parameter that balances the coefficient shrinking effect. The package `nnet`, as implemented in `caret`'s `train()` function was used in this case.

A method to treat multi-collinearity and high dimensionality is a 2-stage Maximum Likelihood (ML) Factor Analysis (FA), such as the one the package `FMradio` [79] performs. In the 1st stage, a L1-regularised ML estimation is used to filter out redundant features from the data matrix. In the second stage, ML FA projects the aforementioned matrix to an orthogonal space where the features are replaced by -fewer- factors that explain their covariance. One can then use the produced factor scores as predictors in MNL.

Decision Trees (DT) are inherently interpretable, non-parametric models, that fit well large and complicated data sets. They have a tree-like structure that splits the data into branches and leaves(nodes) [98]. The `rpart2()` [99] function of `rpart` was used.

Random Forests (RF) are ensemble learning methods, that bag several DTs and average their decisions with a majority vote. Despite RFs tend to outperform DTs, they often operate as a *black box* and are poorly interpretable. The state-of-the-art ensemble learner `xgbTree` of the package `xgboost` [100] was used.

The aforementioned models were hyper-parameter tuned over a grid of values and the best was selected using repeated (100 times) 10-fold Cross-Validation (CV). The best model's performance was then holistically assessed using repeated 10-fold CV-obtained Area Under the ROC curve (AUC) using the `pROC` package [101] and other metrics such as Accuracy, Precision, Recall and F1-score from `caret`.

3.4.4. *Network analysis.* Network science offers a unifying framework for data and system representation, applicable to any domain [102]. A network, in an abstract sense, consists of nodes connected with links, also referred to as edges. In data science, a network whose nodes represent random features, whose joint probability distribution is defined by the ensemble of their edges is called *graphical model* [80]. A metabolomic covariance correlation network represents the ensemble of metabolites based on their covariance, showing nuances among the samples that non-graphical statistical methods on individual metabolites may fail to detect [103]. It may provide insights into correlated metabolites that don't belong in the same metabolic pathway [103].

A *Gaussian graphical model* (GGM) is an undirected graph that represents the conditional independence properties of the features [104]. The statistic employed by GGMs is the partial correlation which also adjusts for indirect correlation, i.e. two metabolites are correlated with a third one and are shown correlated with each other [105]. For instance, let $\mathcal{G} = (\mathcal{V}, \mathcal{E})$ be a GGM consisting of a set \mathcal{V} of p vertices, corresponding to random features Y_1, \dots, Y_p with joint probability distribution $P \sim N_p(\mathbf{0}, \mathbf{\Sigma})$, and set of edges \mathcal{E} , such that for all pairs $\{Y_i, Y_j\}$ with $i \neq j$:

$$\Sigma_{ij}^{-1} = (\mathbf{\Omega}_{ij}) = 0 \iff Y_i \perp\!\!\!\perp Y_j \mid \{Y_k : k \neq i, j\} \iff (i, j) \notin \mathcal{E}$$

In natural language, a zero value in the inverse covariance matrix (usually referred to as precision matrix $\mathbf{\Omega}$) implies that the respective random features are independent, given the rest of features, and they are not connected by an undirected edge ($(i, j) \notin \mathcal{E}$) [80].

In this study, the package `rag2ridges` [80] was used to generate the feature covariance matrix, as well as the precision matrix, regularise it and represent it in a GGM—as shown in Fig. 2. The package was designed for metabolomic GGMs.

3.5. R Packages.

caret [94]
dplyr [83]
DMwR2 [95]
globaltest [86–88]

GlobalAncova [89–91]
heatmaply [106]
FMradio [79]
nnet [107]

pROC [101]
rags2ridges [80]
rpart [99]
xgboost [100]

4. RESULTS

4.1. Data Exploration and Visualisation. The ApoE allele and genotype frequencies in the population are reflected in the AD and SCD data, as shown in Table 1. That is, the most abundant allele is $\epsilon 3$, followed by $\epsilon 4$ and $\epsilon 2$. The most common genotype was $\epsilon 3\epsilon 3$, followed by $\epsilon 3\epsilon 4$ and $\epsilon 4\epsilon 4$.

TABLE 1. Individual ApoE genotype counts among SCD and AD patients.

$\epsilon 2\epsilon 2$	$\epsilon 2\epsilon 3$	$\epsilon 2\epsilon 4$	$\epsilon 3\epsilon 3$	$\epsilon 3\epsilon 4$	$\epsilon 4\epsilon 4$
2	18	7	106	85	29

The genotypes are not equally represented in the data and hence, don't enable analysis without feature engineering. The following two sections describe the features created to balance the classes when studying only the AD group and both AD and SCD.

4.1.1. AD group. An obvious and "low-res" approach would be to bin the samples into two groups: those carrying at least one $\epsilon 4$ allele, and $\epsilon 4$ non-carriers. However, in order to study the $\epsilon 4$ dose effects, the genotypes can be binned into groups, based on the number of $\epsilon 4$ alleles they carry: 0, 1 or 2. The frequencies of $\epsilon 4$ doses are shown in Table 3.

TABLE 2. Individual ApoE genotype counts among AD patients.

$\epsilon 2\epsilon 2$	$\epsilon 2\epsilon 3$	$\epsilon 2\epsilon 4$	$\epsilon 3\epsilon 3$	$\epsilon 3\epsilon 4$	$\epsilon 4\epsilon 4$
0	3	2	37	59	26

TABLE 3. ApoE $\epsilon 4$ dose frequencies among AD patients.

No $\epsilon 4$	1x $\epsilon 4$	2x $\epsilon 4$
40	61	26

4.1.2. SCD and AD. In order to incorporate the presence of $\epsilon 4$, as well as the diagnosis, a four-level feature ("ApoE4AD") was created, as shown in Table 4.

TABLE 4. Feature combining ApoE4 status and AD diagnosis.

	$\geq 1 \epsilon 4$	no $\epsilon 4$
AD	34	86
SCD	87	40

4.2. RQi - Differential expression of plasma metabolites per ApoE4 dose among AD and SCD.

4.2.1. Global Test.

4.2.2. Hierarchical Global ANCOVA on Generalised Linear Models.

4.2.3. ANOVA on Nested Linear Models.

4.3. RQii - Classification of metabolites on ApoE4 presence.

4.3.1. *Benchmark model: clinical factors only.*

4.3.2. *Fitting the full metabolomic panel, correcting for clinical factors.*

4.3.3. *Fitting the metabolomic ML-estimated 6-factor Latent Projection.*

4.4. RQiii - Covariance Network analysis of metabolites.

5. DISCUSSION

6. CONCLUSION

REFERENCES

1. Penke, B., Szűcs, M. & Bogár, F. New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer's Disease. *International Journal of Molecular Sciences* **24**, 5383. issn: 1422-0067. <https://www.mdpi.com/1422-0067/24/6/5383> (Mar. 2023).
2. 2023 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* **19**, 1598–1695. issn: 1552-5279. <https://onlinelibrary.wiley.com/doi/full/10.1002/alz.13016> <https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.13016> <https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13016> (Apr. 2023).
3. Heneka, M. T. *et al.* Neuroinflammation in Alzheimer's disease. *The Lancet. Neurology* **14**, 388–405. issn: 1474-4465. <https://pubmed.ncbi.nlm.nih.gov/25792098/> (Apr. 2015).
4. Edwards, F. A. A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration. *Trends in Neurosciences* **42**, 310–322. issn: 1878108X. <http://www.cell.com/article/S016622361930027X/fulltext> <http://www.cell.com/article/S016622361930027X/abstract> [https://www.cell.com/trends/neurosciences/abstract/S0166-2236\(19\)30027-X](https://www.cell.com/trends/neurosciences/abstract/S0166-2236(19)30027-X) (May 2019).
5. Rasmussen, J. & Langerman, H. Alzheimer's Disease – Why We Need Early Diagnosis. *Degenerative Neurological and Neuromuscular Disease* **9**, 123. <https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC6935598/> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935598/?report=abstract> (Dec. 2019).
6. Scheltens, P. *et al.* Alzheimer's disease. *Lancet (London, England)* **388**, 505–517. issn: 1474-547X. <https://pubmed.ncbi.nlm.nih.gov/26921134/> (July 2016).
7. Beydoun, M. A. *et al.* Epidemiologic studies of modifiable factors associated with cognition and dementia: Systematic review and meta-analysis. *BMC Public Health* **14**, 1–33. issn: 14712458. <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-643> (June 2014).
8. Van Cauwenberghe, C., Van Broeckhoven, C. & Sleegers, K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. *Genetics in Medicine* **18**, 421–430. issn: 1530-0366. <https://www.nature.com/articles/gim2015117> (Aug. 2015).
9. Hardy, J. Alzheimer's disease: The amyloid cascade hypothesis: An update and reappraisal. *Journal of Alzheimer's Disease* **9**, 151–153. issn: 1387-2877 (Jan. 2006).
10. Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L. & Vissel, B. The amyloid cascade hypothesis: an updated critical review. <https://doi.org/10.1093/brain/awad159> (2023).
11. Kurkinen, M. *et al.* The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking? *Biomolecules* **2023**, Vol. 13, Page 453 **13**, 453. issn: 2218-273X. <https://www.mdpi.com/2218-273X/13/3/453/htm> <https://www.mdpi.com/2218-273X/13/3/453> (Mar. 2023).
12. Corder, E. H. *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921–923. issn: 00368075 (Aug. 1993).
13. Husain, M. A., Laurent, B. & Plourde, M. APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. *Frontiers in Neuroscience* **15**, 630502. issn: 1662453X (Feb. 2021).
14. Yang, L. G., March, Z. M., Stephenson, R. A. & Narayan, P. S. Apolipoprotein E in lipid metabolism and neurodegenerative disease. *Trends in Endocrinology & Metabolism* **34**, 430–445. issn: 1043-2760. <http://www.cell.com/article/S1043276023000929/fulltext> <http://www.cell.com/article/S1043276023000929/abstract> [https://www.cell.com/trends/endocrinology-metabolism/abstract/S1043-2760\(23\)00092-9](https://www.cell.com/trends/endocrinology-metabolism/abstract/S1043-2760(23)00092-9) (Aug. 2023).
15. Liu, C. & *al. et, e.* Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. *Nat. Rev. Neurosci.* **9**, 106–118 (2013).
16. Strittmatter, W. & *al. et, e.* Apolipoprotein E: high-avidity binding to β -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 1977–1981 (1993).
17. Deming, Y. & *al. et, e.* Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. *Acta Neuropathol.* **133**, 839–856 (2017).
18. Belloy, M. & *al. et, e.* A quarter century of APOE and Alzheimer's disease: progress to date and the path forward. *Neuron* **101**, 820–838 (2019).
19. Farrer, L. & *al. et, e.* Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. *JAMA* **278**, 1349–1356 (1997).
20. Egert, S., Rimbach, G. & Huebbe, P. ApoE genotype: from geographic distribution to function and responsiveness to dietary factors. *Proceedings of the Nutrition Society* **71**, 410–424. issn: 1475-2719. <https://www.cambridge.org/core/journals/proceedings-of-the-nutrition-society/article/apoe-genotype-from-geographic-distribution-to-function-and-responsiveness-to-dietary-factors/D9F35B3FFE46F48CAFE131E0E94CC62C> (Aug. 2012).
21. Eisenberg, D. T., Kuzawa, C. W. & Hayes, M. G. Worldwide allele frequencies of the human apolipoprotein E gene: Climate, local adaptations, and evolutionary history. *American Journal of Physical Anthropology* **143**, 100–111. issn: 1096-8644. <https://onlinelibrary.wiley.com/doi/full/10.1002/ajpa.21298> <https://onlinelibrary.wiley.com/doi/abs/10.1002/ajpa.21298> (Sept. 2010).

22. Logue, M. W. *et al.* A Comprehensive Genetic Association Study of Alzheimer Disease in African Americans. *Archives of Neurology* **68**, 1569–1579. issn: 0003-9942. <https://jamanetwork.com/journals/jamaneurology/fullarticle/1108047> (Dec. 2011).
23. Blue, E. E., Horimoto, A. R., Mukherjee, S., Wijsman, E. M. & Thornton, T. A. Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics. *Alzheimer's & Dementia* **15**, 1524–1532. issn: 1552-5279. <https://onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2019.07.016><https://onlinelibrary.wiley.com/doi/abs/10.1016/j.jalz.2019.07.016><https://alz-journals.onlinelibrary.wiley.com/doi/10.1016/j.jalz.2019.07.016> (Dec. 2019).
24. Suchy-Dacey, A., Howard, B., Longstreth, W. T., Reiman, E. M. & Buchwald, D. APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study. *Alzheimer's & Dementia* **18**, 2518–2526. issn: 1552-5279. <https://onlinelibrary.wiley.com/doi/full/10.1002/alz.12573><https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.12573><https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12573> (Dec. 2022).
25. Rajabli, F. *et al.* Ancestral origin of ApoE ϵ 4 Alzheimer disease risk in Puerto Rican and African American populations. *PLOS Genetics* **14**, e1007791. issn: 1553-7404. <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1007791> (Dec. 2018).
26. Naslavsky, M. S. *et al.* Global and local ancestry modulate APOE association with Alzheimer's neuropathology and cognitive outcomes in an admixed sample. *Molecular Psychiatry* **27**, 4800–4808. issn: 1476-5578. <https://www.nature.com/articles/s41380-022-01729-x> (Sept. 2022).
27. Chen, H.-K. & al. et, e. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. *J. Biol. Chem.* **286**, 5215–5221 (2011).
28. Rajabli, F. *et al.* A locus at 19q13.31 significantly reduces the ApoE ϵ 4 risk for Alzheimer's Disease in African Ancestry. *PLOS Genetics* **18**, e1009977. issn: 1553-7404. <https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1009977> (July 2022).
29. Arnold, M. E. Sex and APOE ϵ 4 genotype modify the Alzheimer's disease serum metabolome. *Nature Communications* **11**, 1–12. issn: 2041-1723. <https://www.nature.com/articles/s41467-020-14959-w> (Mar. 2020).
30. Yassine, H. N. & Finch, C. E. APOE Alleles and Diet in Brain Aging and Alzheimer's Disease. *Frontiers in Aging Neuroscience* **12**, 544681. issn: 16634365 (June 2020).
31. Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V. & Reed, M. N. The role of APOE4 in Alzheimer's disease: strategies for future therapeutic interventions. *Neuronal Signaling* **3**, 1–15. issn: 20596553. <https://neuronalsignal/article/3/2/NS20180203/110989/The-role-of-APOE4-in-Alzheimer-s-disease><https://dx.doi.org/10.1042/NS20180203> (June 2019).
32. Trumble, B. C. *et al.* Apolipoprotein E4 is associated with improved cognitive function in Amazonian forager-horticulturalists with a high parasite burden. *FASEB Journal* **31**, 1508–1515. issn: 15306860 (Apr. 2017).
33. Finch, C. E. & Sapolsky, R. M. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. *Neurobiology of Aging* **20**, 407–428. issn: 01974580 (1999).
34. Mahley, R. Central nervous system lipoproteins: ApoE and regulation of cholesterol metabolism. *Arterioscler. Thromb. Vasc. Biol.* **36**, 1305–1315 (2016).
35. Lanfranco, M. & al. et, e. Expression and secretion of apoE isoforms in astrocytes and microglia during inflammation. *Glia* **69**, 1478–1493 (2021).
36. Castellano, J. M. *et al.* Human apoE isoforms differentially regulate brain amyloid- β peptide clearance. *Science Translational Medicine* **3**. issn: 19466234 (June 2011).
37. Cruchaga, C. *et al.* Cerebrospinal fluid APOE levels: An endophenotype for genetic studies for Alzheimer's disease. *Human Molecular Genetics* **21**, 4558–4571. issn: 09646906 (Oct. 2012).
38. Bu, G. APOE targeting strategy in Alzheimer's disease: lessons learned from protective variants. *Molecular Neurodegeneration* **17**, 1–4. issn: 17501326. <https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-022-00556-6> (Dec. 2022).
39. Hu, J. *et al.* Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and A β metabolism in apoE4-targeted replacement mice. *Molecular Neurodegeneration* **10**, 1–11. issn: 17501326. <https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-015-0001-3> (Mar. 2015).
40. Flowers, S. A. & Rebeck, G. W. APOE in the normal brain. *Neurobiology of Disease* **136**, 104724. issn: 0969-9961 (Mar. 2020).
41. Courtney, R. & Landreth, G. E. LXR Regulation of Brain Cholesterol: From Development to Disease. *Trends in Endocrinology and Metabolism* **27**, 404–414. issn: 18793061. <http://www.cell.com/article/S1043276016300042/fulltext><https://www.cell.com/article/S1043276016300042/abstract>[https://www.cell.com/trends/endocrinology-metabolism/abstract/S1043-2760\(16\)30004-2](https://www.cell.com/trends/endocrinology-metabolism/abstract/S1043-2760(16)30004-2) (June 2016).
42. Heinsinger, N. M., Gachechiladze, M. A. & Rebeck, G. W. Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid. *Journal of Neuropathology & Experimental Neurology* **75**, 918–924. issn: 0022-3069. <https://dx.doi.org/10.1093/jnen/nlw067> (Oct. 2016).

43. Nguyen, D. *et al.* Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. *Biochemistry* **49**, 10881–10889. ISSN: 00062960. <https://pubs.acs.org/doi/abs/10.1021/bi1017655> (Dec. 2010).
44. Hatters, D. M., Peters-Libeu, C. A. & Weisgraber, K. H. Apolipoprotein E structure: insights into function. *Trends in Biochemical Sciences* **31**, 445–454. ISSN: 09680004 (Aug. 2006).
45. Hatters, D. M., Zhong, N., Rutenber, E. & Weisgraber, K. H. Amino-terminal Domain Stability Mediates Apolipoprotein E Aggregation into Neurotoxic Fibrils. *Journal of Molecular Biology* **361**, 932–944. ISSN: 00222836 (Sept. 2006).
46. Rawat, V. *et al.* ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes. *Journal of Neuroscience* **39**, 9611–9622. ISSN: 0270-6474. <https://www.jneurosci.org/content/39/48/9611> <https://www.jneurosci.org/content/39/48/9611.abstract> (Nov. 2019).
47. Zhao, N. *et al.* Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. *Neuron* **96**, 115–129. ISSN: 1097-4199. <https://pubmed.ncbi.nlm.nih.gov/28957663/> (Sept. 2017).
48. Svennerholm, L., Boström, K. & Jungbjer, B. Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes. *Acta Neuropathologica* **94**, 345–352. ISSN: 00016322. <https://link.springer.com/article/10.1007/s004010050717> (Oct. 1997).
49. Marottoli, F. M. *et al.* Peripheral inflammation, apolipoprotein E4, and amyloid- β interact to induce cognitive and cerebrovascular dysfunction. *ASN Neuro* **9**. ISSN: 17590914. <https://journals.sagepub.com/doi/10.1177/1759091417719201> (Aug. 2017).
50. Teng, Z. *et al.* ApoE Influences the Blood-Brain Barrier Through the NF- κ B/MMP-9 Pathway After Traumatic Brain Injury. *Scientific Reports* **2017 7:1** **7**, 1–8. ISSN: 2045-2322. <https://www.nature.com/articles/s41598-017-06932-3> (July 2017).
51. Kloske, C. M. & Wilcock, D. M. The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease. *Frontiers in Immunology* **11**. ISSN: 16643224 (Apr. 2020).
52. Huang, Y. W. A., Zhou, B., Wernig, M. & Südhof, T. C. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and A β Secretion. *Cell* **168**, 427–441. ISSN: 10974172 (Jan. 2017).
53. Tachibana, M. *et al.* Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1. *Experimental Neurology* **277**, 1–9. ISSN: 0014-4886 (Mar. 2016).
54. Safieh, M., Karczyn, A. D. & Michaelson, D. M. ApoE4: an emerging therapeutic target for Alzheimer's disease. *BMC Medicine* **2019 17:1** **17**, 1–17. ISSN: 1741-7015. <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-019-1299-4> (Mar. 2019).
55. Cao, J. *et al.* ApoE4-associated phospholipid dysregulation contributes to development of Tau hyper-phosphorylation after traumatic brain injury. *Scientific Reports* **7**. ISSN: 20452322 (Dec. 2017).
56. Shi, Y. *et al.* ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature* **2017 549:7673** **549**, 523–527. ISSN: 1476-4687. <https://www.nature.com/articles/nature24016> (Sept. 2017).
57. Vasilevskaya, A. *et al.* Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes. *NeuroImage: Clinical* **26**, 102212. ISSN: 2213-1582 (Jan. 2020).
58. Wang, C. & *al. et.* Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. *Nat. Med.* **24**, 647–657 (2018).
59. Hoe, H. S., Freeman, J. & Rebeck, G. W. Apolipoprotein e decreases tau kinases and phospho-tau levels in primary neurons. *Molecular Neurodegeneration* **1**. ISSN: 17501326 (2006).
60. Barupal, D. K. *et al.* Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **11**, 619–627. ISSN: 2352-8729 (Dec. 2019).
61. Fernández-Calle, R. *et al.* APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases. *Molecular Neurodegeneration* **2022 17:1** **17**, 1–47. ISSN: 1750-1326. <https://link.springer.com/articles/10.1186/s13024-022-00566-4> <https://link.springer.com/article/10.1186/s13024-022-00566-4> (Sept. 2022).
62. Proitsi, P. *et al.* Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. *Alzheimer's & Dementia* **13**, 140–151. ISSN: 1552-5260 (Feb. 2017).
63. Oeckl, P. *et al.* Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment. *Journal of Alzheimer's disease : JAD* **67**, 481–488. ISSN: 1875-8908. <https://pubmed.ncbi.nlm.nih.gov/30594925/> (2019).
64. Bandaru, V. V. R. *et al.* ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. *Neurobiology of Aging* **30**, 591–599. ISSN: 0197-4580 (Apr. 2009).
65. Novotny, B. C. *et al.* Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer's disease brains. *Alzheimer's & Dementia* **19**, 1785–1799. ISSN: 1552-5279. <https://onlinelibrary.wiley.com/doi/full/10.1002/alz.12800> <https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.12800> <https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12800> (May 2023).

66. Area-Gomez, E. *et al.* APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice. *Scientific Reports* 2020 10:1 **10**, 1–20. ISSN: 2045-2322. <https://www.nature.com/articles/s41598-020-61142-8> (Mar. 2020).
67. Zhao, N. *et al.* Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. *Neuron* **106**, 727–742. ISSN: 10974199. [http://www.cell.com/article/S0896627320301859/fulltext%20http://www.cell.com/article/S0896627320301859/abstract%20https://www.cell.com/neuron/abstract/S0896-6273\(20\)30185-9](http://www.cell.com/article/S0896627320301859/fulltext%20http://www.cell.com/article/S0896627320301859/abstract%20https://www.cell.com/neuron/abstract/S0896-6273(20)30185-9) (June 2020).
68. Peña-bautista carmen, c. *et al.* Metabolomics study to identify plasma biomarkers in alzheimer disease: ApoE genotype effect. *Journal of Pharmaceutical and Biomedical Analysis* **180**, 113088. ISSN: 0731-7085 (Feb. 2020).
69. Farmer, B. & al. et, e. APOE4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis. *Mol. Neurodegener.* **16**, 62 (2021).
70. De Leeuw, F. A. *et al.* Blood-based metabolic signatures in Alzheimer's disease. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **8**, 196–207. ISSN: 2352-8729 (Jan. 2017).
71. Green, R. E. *et al.* Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease. *Alzheimer's Research and Therapy* **15**, 1–13. ISSN: 17589193. <https://alzres.biomedcentral.com/articles/10.1186/s13195-023-01184-y%20http://creativecommons.org/publicdomain/zero/1.0/> (Dec. 2023).
72. Varma, V. R. *et al.* Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. *PLOS Medicine* **15**, e1002482. ISSN: 1549-1676. <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002482> (Jan. 2018).
73. Sun, L. *et al.* Association between Human Blood Metabolome and the Risk of Alzheimer's Disease. *Annals of Neurology* **92**, 756–767. ISSN: 1531-8249. <https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26464%20https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.26464%20https://onlinelibrary.wiley.com/doi/10.1002/ana.26464> (Nov. 2022).
74. Jia, L. *et al.* A metabolite panel that differentiates Alzheimer's disease from other dementia types. *Alzheimer's & Dementia* **18**, 1345–1356. ISSN: 1552-5279. <https://onlinelibrary.wiley.com/doi/full/10.1002/alz.12484%20https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.12484%20https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12484> (July 2022).
75. Huo, Z. *et al.* Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis. *Neurobiology of Aging* **86**, 123–133. ISSN: 0197-4580 (Feb. 2020).
76. Weng, W. C., Huang, W. Y., Tang, H. Y., Cheng, M. L. & Chen, K. H. The Differences of Serum Metabolites Between Patients With Early-Stage Alzheimer's Disease and Mild Cognitive Impairment. *Frontiers in Neurology* **10**, 482026. ISSN: 16642295 (Nov. 2019).
77. Simpson, B. N. *et al.* Blood metabolite markers of cognitive performance and brain function in aging. *Journal of Cerebral Blood Flow and Metabolism* **36**, 1212–1223. ISSN: 15597016. <https://journals.sagepub.com/doi/full/10.1177/0271678X15611678> (July 2016).
78. Oka, T., Matsuzawa, Y., Tsuneyoshi, M. & Nakamura, Y. Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort. <https://www.researchsquare.com/article/rs-2973576/v1> (June 2023).
79. Peeters, C. F. W. *et al.* Stable prediction with radiomics data. <https://arxiv.org/abs/1903.11696v1> (Mar. 2019).
80. Peeters, C. F., Bilgrau, A. E. & van Wieringen, W. N. rags2ridges: A One-Stop-2-Shop for Graphical Modeling of High-Dimensional Precision Matrices. *Journal of Statistical Software* **102**, 1–32. ISSN: 1548-7660. <https://www.jstatsoft.org/index.php/jss/article/view/v102i04> (May 2022).
81. Van Der Flier, W. M. & Scheltens, P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. *Journal of Alzheimer's disease : JAD* **62**, 1091–1111. ISSN: 1875-8908. <https://pubmed.ncbi.nlm.nih.gov/29562540/> (2018).
82. Wilkinson, M. D. *et al.* The FAIR Guiding Principles for scientific data management and stewardship. *Scientific Data* 2016 3:1 **3**, 1–9. ISSN: 2052-4463. <https://www.nature.com/articles/sdata201618> (Mar. 2016).
83. Wickham, H., François, R., Henry, L., Müller, K. & Vaughan, D. *dplyr: A Grammar of Data Manipulation* R package version 1.1.4, <https://github.com/tidyverse/dplyr> (2023). <https://dplyr.tidyverse.org>.
84. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)* **57**, 289–300. ISSN: 00359246 (1995).
85. Simon, R. M. *et al.* Design and Analysis of DNA Microarray Investigations Series: Statistics for Biology and Health, 199 (2004).
86. Goeman, J. J., Van de Geer, S., De Kort, F. & van Houwelingen, H. C. A global test for groups of genes: testing association with a clinical outcome. *Bioinformatics (Oxford, England)* **20**, 93–99. ISSN: 1367-4803. <https://pubmed.ncbi.nlm.nih.gov/14693814/> (Jan. 2004).
87. Goeman, J. J., Van De Geer, S. A. & Van Houwelingen, H. C. Testing against a high dimensional alternative. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **68**, 477–493. ISSN: 1467-9868. <https://onlinelibrary.wiley.com/doi/full/10.1111/j.1467-9868.2006.00551.x%20https://onlinelibrary.wiley.com/doi/abs/>

- 10.1111/j.1467-9868.2006.00551.x%20https://rss.onlinelibrary.wiley.com/doi/10.1111/j.1467-9868.2006.00551.x (June 2006).
88. Goeman, J., Oosting, J., Finos, L., Solari, A. & Edelman, D. The Global Test and the globaltest R package (2023).
89. Mansmann, U. & Meister, R. Testing differential gene expression in functional groups: Goeman's global test versus an ANCOVA approach. *Methods of Information in Medicine* **44**, 449–453. issn: 00261270. <http://www.thieme-connect.com/products/ejournals/html/10.1055/s-0038-1633992%20http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1633992> (2005).
90. Hummel, M., Meister, R. & Mansmann, U. GlobalANCOVA: exploration and assessment of gene group effects. *Bioinformatics (Oxford, England)* **24**, 78–85. issn: 1367-4811. <https://pubmed.ncbi.nlm.nih.gov/18024976/> (Jan. 2008).
91. Hummel, M., Meister, R. & Mansmann, U. Global testing of differential gene expression (2023).
92. Elshawi, R., Al-Mallah, M. H. & Sakr, S. On the interpretability of machine learning-based model for predicting hypertension. *BMC Medical Informatics and Decision Making* **19**, 1–32. issn: 14726947. <https://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-019-0874-0> (July 2019).
93. Geman, S., Bienenstock, E. & Doursat, R. Neural Networks and the Bias/Variance Dilemma. *Neural Computation* **4**, 1–58. issn: 0899-7667. <https://dx.doi.org/10.1162/neco.1992.4.1.1> (Jan. 1992).
94. Kuhn, M. Building Predictive Models in R Using the caret Package. *Journal of Statistical Software* **28**, 1–26. issn: 1548-7660. <https://www.jstatsoft.org/index.php/jss/article/view/v028i05> (Nov. 2008).
95. Torgo, L. *Data Mining with R, learning with case studies, 2nd edition* <http://ltorgo.github.io/DMwR2> (Chapman and Hall/CRC, 2016).
96. James, G., Witten, D., Hastie, T. & Tibshirani, R. *An Introduction to Statistical Learning with Applications in R Second Edition* (2023).
97. Tibshirani, R. Regression Shrinkage and Selection Via the Lasso. *Journal of the Royal Statistical Society: Series B (Methodological)* **58**, 267–288. issn: 2517-6161. <https://onlinelibrary.wiley.com/doi/full/10.1111/j.2517-6161.1996.tb02080.x%20https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2517-6161.1996.tb02080.x%20https://rss.onlinelibrary.wiley.com/doi/10.1111/j.2517-6161.1996.tb02080.x> (Jan. 1996).
98. Song, Y. Y. & Lu, Y. Decision tree methods: applications for classification and prediction. *Shanghai Archives of Psychiatry* **27**, 130. issn: 10020829. <https://pubmed.ncbi.nlm.nih.gov/pmc/articles/PMC4466856/> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466856/?report=abstract%20https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466856/> (Apr. 2015).
99. Therneau, T. M., Atkinson, B., Ripley, B., *et al.* rpart: Recursive partitioning. *R package version 3* (2010).
100. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining* **13-17-August-2016**, 785–794. <https://arxiv.org/abs/1603.02754v3> (Mar. 2016).
101. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* **12**, 77 (2011).
102. Barabási, A.-L. *Network Science* <http://networksciencebook.com/> (Cambridge University Press, 2015).
103. Perez De Souza, L., Alseekh, S., Brotman, Y. & Fernie, A. R. Network-based strategies in metabolomics data analysis and interpretation: from molecular networking to biological interpretation. *Expert Review of Proteomics* **17**, 243–255. issn: 17448387 (Apr. 2020).
104. Koller, D. & Friedman, N. Probabilistic Graphical Models: Principles and Techniques.
105. Amara, A. *et al.* Networks and Graphs Discovery in Metabolomics Data Analysis and Interpretation. *Frontiers in Molecular Biosciences* **9**, 841373. issn: 2296889X (Mar. 2022).
106. Galili *et al.* heatmaply: an R package for creating interactive cluster heatmaps for online publishing. *Bioinformatics*. <https://academic.oup.com/bioinformatics/article-pdf/doi/10.1093/bioinformatics/btx657/21358327/btx657.pdf> (2017).
107. Venables, W. N. & Ripley, B. D. *Modern Applied Statistics with S Fourth*. ISBN 0-387-95457-0. <https://www.stats.ox.ac.uk/pub/MASS4/> (Springer, New York, 2002).